Erbb targeted drugs and angiogenesis

Current Vascular Pharmacology

Volumn 8, Issue 3, 2010, Pages 421-431

  Iivanainen, Erika ^a   Elenius, Klaus ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Anti angiogenic drugs; Cancer; EGFR; Endothelial cells; Her; Monoclonal antibodies; Pericytes; Smooth muscle cells; Tyrosine kinase inhibitors

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; LAPATINIB; LIGAND; PANITUMUMAB; TRASTUZUMAB; VANDETANIB;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COLORECTAL CANCER; DEVELOPMENT; DRUG EFFECT; EXPERIMENTAL STUDY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; NONHUMAN; PANCREAS CARCINOMA; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77952920187     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791112241     Document Type: Article

References (128)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333(2): 328-35.
3. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
4. van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005; 117(6): 883-8.
5. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008; 214: 559-67.
6. Klos K, Wyszomierski S, Sun M, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66: 2028-37.
7. Iivanainen E, Lauttia S, Zhang N, et al. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvasc Res 2009; 78: 278-85.
8. Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-35.
9. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
10. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005; 7: 452-64.
11. Lamagna C, Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. J Leukoc Biol 2006; 80: 677-81.
12. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80.
13. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11: 689-708.
14. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-67.
15. Elenius K, Paul S, Allison G, et al. Activation of HER4 by heparin binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 1997; 16: 1268-78.
16. Stern D. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2000; 2: 176-83.
17. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
18. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003; 284: 14-30.
19. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 1993; 122: 933-40.
20. Nishi E, Prat A, Hospital V, et al. N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration. EMBO J 2001; 20: 3342-50.
21. Iivanainen E, Paatero I, Heikkinen S, et al. Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res 2007; 313: 2896-909.
22. Bao J, Wolpowitz D, Role LW, et al. Back signaling by the Nrg-1 intracellular domain. J Cell Biol 2003; 161: 1133-41.
23. Naglich JG, Metherall JE, Russell DW, et al. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 1992; 69: 1051-61.
24. Iwamoto R, Higashiyama S, Mitamura T, et al. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which upregulates functional receptors and diphtheria toxin sensitivity. EMBO J 1994; 13: 2322-30.
25. Stern D. ErbBs in mammary development. Exp Cell Res 2003; 284: 89-98.
26. Iwamoto R, Mekada E. ErbB and HB-EGF signaling in heart development and function. Cell Struct Funct 2006; 31: 1-14.
27. Sibilia M, Kroismayr R, Lichtenberger B, et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75: 770-87.
28. Mei L, Xiong W. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008; 9: 437-52.
29. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390-4.
30. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-8.
31. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-90.
32. Marchionni MA. Cell-cell signalling. neu tack on neuregulin. Nature 1995; 378: 334-5.
33. Chen B, Bronson RT, Klaman LD, et al. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet 2000; 24: 296-9.
34. Iwamoto R, Yamazaki S, Asakura M, et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 2003; 100: 3221-6.
35. Jackson LF, Qiu TH, Sunnarborg SW, et al. Defective valvulo-genesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 2003; 22: 2704-16.
36. Erickson SL, O'Shea KS, Ghaboosi N, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 1997; 124: 4999-5011.
37. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16.
38. Schulze W, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005; 1: 2005.0008.
39. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-83.
40. Nanba D, Kinugasa Y, Morimoto C, et al. Loss of HB-EGF in smooth muscle or endothelial cell lineages causes heart malformation. Biochem Biophys Res Commun 2006; 350: 315-21.
41. Iivanainen E, Nelimarkka L, Elenius V, et al. Angiopoietin regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J 2003; 17: 1609-21.
42. Kim SJ, Uehara H, Karashima T, et al. Blockade of epidermal growth factor receptor signaling in tumor cells and tumorassociated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003; 9: 1200-10.
43. Amin DN, Hida K, Bielenberg DR, et al. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006; 66: 2173-80.
44. Baker CH, Kedar D, McCarty MF, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002; 161: 929-38.
45. McAuslan BR, Bender V, Reilly W, et al. New functions of epidermal growth factor: stimulation of capillary endothelial cell migration and matrix dependent proliferation. Cell Biol Int Rep 1985; 9: 175-82.
46. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250-3.
47. Okamura K, Morimoto A, Hamanaka R, et al. A model system for tumor angiogenesis: involvement of transforming growth factor-alpha in tube formation of human microvascular endothelial cells induced by esophageal cancer cells. Biochem Biophys Res Commun 1992; 186: 1471-9.
48. Ushiro S, Ono M, Izumi H, et al. Heparin-binding epidermal growth factor-like growth factor: p91 activation induction of plasminogen activator/inhibitor, and tubular morphogenesis in human microvascular endothelial cells. Jpn J Cancer Res 1996; 87: 68-77.
49. Abramovitch R, Neeman M, Reich R, et al. Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor. FEBS Lett 1998; 425: 441-7.
50. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-60.
51. Kim HS, Shin HS, Kwak HJ, et al. Betacellulin induces angiogenesis through activation of mitogen-activated protein kinase and phosphatidylinositol 3'-kinase in endothelial cell. FASEB J 2003; 17: 318-20.
52. Gospodarowicz D, Bialecki H, Thakral TK. The angiogenic activity of the fibroblast and epidermal growth factor. Exp Eye Res 1979; 28: 501-14.
53. Higashiyama S, Abraham JA, Miller J, et al. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251: 936-9.
54. Taylor DS, Cheng X, Pawlowski JE, et al. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci USA 1999; 96: 1633-8.
55. Tamura R, Miyagawa J, Nishida M, et al. Immunohistochemical localization of Betacellulin, a member of epidermal growth factor family, in atherosclerotic plaques of human aorta. Atherosclerosis 2001; 155: 413-23.
56. Kato M, Inazu T, Kawai Y, et al. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5. Biochem Biophys Res Commun 2003; 301: 1109-15.
57. Takahashi M, Hayashi K, Yoshida K, et al. Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells. Circulation 2003; 108: 2524-9.
58. Mifune M, Ohtsu H, Suzuki H, et al. Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. Am J Physiol Cell Physiol 2004; 287: C807-13.
59. Hellstrom M, Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999; 126: 3047-55.
60. Purhonen S, Palm J, Rossi D, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 2008; 105: 6620-5.
61. Russell KS, Stern DF, Polverini PJ, et al. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol 1999; 277(6 Pt 2): H2205-11.
62. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19: 3460-9.
63. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, et al. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 2000; 275: 39451-7.
64. Clement CM, Thomas LK, Mou Y, et al. Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J Vasc Res 2007; 44: 303-12.
65. Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme patho-physiology. Mol Biol Cell 1993; 4: 121-33.
66. O-charoenrat P, Rhys-Evans P, Modjtahedi H, et al. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 2000; 18: 155-61.
67. Akagi M, Kawaguchi M, Liu W, et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer 2003; 88: 796-802.
68. Ueda S, Basaki Y, Yoshie M, et al. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res 2006; 66: 5346-53.
69. Ueno Y, Sakurai H, Tsunoda S, et al. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008; 123: 340-7.
70. Nanba D, Mammoto A, Hashimoto K, et al. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003; 163: 489-502.
71. Brown M, Ye J, Rawson R, et al. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 2000; 100: 391-8.
72. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454: 656-60.
73. Friedländer E, Barok M, Szöllosi J, et al. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 2008; 116: 126-40.
74. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
75. Cameron D. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Clin Adv Hematol Oncol 2007; 5: 456-8.
76. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
77. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86.
78. Hirata A, Uehara H, Izumi K, et al. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Sci 2004; 95: 614-8.
79. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006; 12: 7242-51.
80. Huang SM, Li J, Armstrong EA, et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002; 62: 4300-6.
81. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 2007; 15: 279-86.
82. Raben D, Bianco C, Damiano V, et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther 2004; 3: 977-83.
83. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30.
84. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5: 257-65.
85. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6: 3739-47.
86. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936-48.
87. th Annual Meeting of the American Association for Cancer Research. San Francisco, USA 2000, p. 290.
88. Foon K, Yang X, Weiner L, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58: 984-90.
89. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Ir-essa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7: 1459-65.
90. Pore N, Jiang Z, Gupta A, et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006; 66: 3197-204.
91. Emlet DR, Brown KA, Kociban DL, et al. Response to trastuzu-mab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007; 6: 2664-74.
92. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006; 25: 6986-96.
93. Niu G, Carter W. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 2007; 67: 1487-93.
94. Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody Im-Clone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8: 1253-64.
95. Morelli MP, Cascone T, Troiani T, et al. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 2006; 208: 344-53.
96. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6: 4874-84.
97. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-8.
98. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002; 1: 507-14.
99. Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 2005; 11: 4521-32.
100. Chen Z, Zhang X, Li M, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10: 5930-9.
101. Amin D, Bielenberg D, Lifshits E, et al. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 2008; 76: 15-22.
102. Yokoi A, McCrudden KW, Huang J, et al. Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor. J Pediatr Surg 2003; 38: 1569-73.
103. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000; 100: 57-70.
104. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931-41.
105. Herbst RS, Heymach JV, O'Reilly MS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007; 16: 239-49.
106. Herrero-Martin G, López-Rivas A. Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins. FEBS Lett 2008; 582: 2589-94.
107. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bonemarrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201.
108. Hanahan D. A flanking attack on cancer. Nat Med 1998; 4: 13-14.
109. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-8.
110. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-95.
111. Saltis J, Thomas AC, Agrotis A, et al. Expression of growth factor receptors in arterial smooth muscle cells. Dependency on cell phenotype and serum factors. Atherosclerosis 1995; 118: 77-87.
112. Tang H, Nishishita T, Fitzgerald T, et al. Inhibition of AT1 receptor internalization by concanavalin A blocks angiotensin II-induced ERK activation in vascular smooth muscle cells. Involvement of epidermal growth factor receptor proteolysis but not AT1 receptor internalization. J Biol Chem 2000; 275: 13420-6.
113. Shin HS, Lee HJ, Nishida M, et al. Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells. Circ Res 2003; 93: 302-10.
114. Ying WZ, Zhang HG, Sanders PW. EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells. J Am Soc Nephrol 2007; 18: 131-42.
115. Zhou W, Ibe BO, Raj JU. Platelet-activating factor induces ovine fetal pulmonary venous smooth muscle cell proliferation: role of epidermal growth factor receptor transactivation. Am J Physiol Heart Circ Physiol 2007; 292: H2773-81.
116. Real FX, Rettig WJ, Chesa PG, et al. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986; 46: 4726-31.
117. Shiurba R, Eng L, Vogel H, et al. Epidermal growth factor receptor in meningiomas is expressed predominantly on endothelial cells. Cancer 1988; 62: 2139-44.
118. Weber K, Doucet M, Price J, et al. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 2003; 63: 2940-7.
119. Thaker P, Yazici S, Nilsson M, et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 2005; 11: 4923-33.
120. Yokoi K, Kim S, Thaker P, et al. Induction of apoptosis in tumor associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia 2005; 7: 696-704.
121. Moon W, Park H, Yu K, et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol 2006; 37: 1324-32.
122. Wakui S, Furusato M, Tanaka M, et al. Endothelium and pericyte interdigitation: pathway for epidermal growth factor? Microvasc Res 1990; 40: 285-91.
123. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000; 50: 121-37.
124. Arkonac BM, Foster LC, Sibinga NE, et al. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J Biol Chem 1998; 273: 4400-5.
125. Dluz SM, Higashiyama S, Damm D, et al. Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells. Induction of mRNA levels and secretion of active mitogen. J Biol Chem 1993; 268: 18330-4.
126. Cote GM, Miller TA, Lebrasseur NK, et al. Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 2005; 311: 135-46.
127. Nakano N, Higashiyama S, Ohmoto H, et al. The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis. J Biol Chem 2004; 279: 11465-70.
128. Hayes N, Newsam R, Baines A, et al. Characterization of the cell membrane-associated products of the Neuregulin 4 gene. Oncogene 2008; 27: 715-20.